Results 241 to 250 of about 320,703 (320)
Long-term pegylated interferon-α and its potential in the treatment of melanoma
, 2009 Reinhard Dummer, Joanna Mangana
openalex +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Science Translational Medicine, 2021
The innate immune response of patients with HBV infection to pegylated interferon therapy is reduced by sequestration of PEG–IFN-α/anti-PEG complexes.
Akira Nishio +8 more
semanticscholar +1 more source
The innate immune response of patients with HBV infection to pegylated interferon therapy is reduced by sequestration of PEG–IFN-α/anti-PEG complexes.
Akira Nishio +8 more
semanticscholar +1 more source
Clinics in Liver Disease, 2003
In summary, pegylated IFNs have a longer half-life, reduced immunogenicity, better pharmacokinetics, and enhanced biological activity when compared with standard IFN. Better adherence rates are feasible because of the once weekly administration of pegylated IFN. The adverse event profile is largely comparable. The improved pharmacokinetics of pegylated
Umaprasanna S, Karnam, K Rajender, Reddy
openaire +4 more sources
In summary, pegylated IFNs have a longer half-life, reduced immunogenicity, better pharmacokinetics, and enhanced biological activity when compared with standard IFN. Better adherence rates are feasible because of the once weekly administration of pegylated IFN. The adverse event profile is largely comparable. The improved pharmacokinetics of pegylated
Umaprasanna S, Karnam, K Rajender, Reddy
openaire +4 more sources
Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
AIDS Reviews, 2019Persistent coinfection with the hepatitis B/D viruses (HDV) represents the most severe form of viral hepatitis. Hepatitis D often leads to liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma. The current treatment options are limited as
K. Deterding, H. Wedemeyer
semanticscholar +1 more source
Ocular immunology and inflammation, 2019
Purpose: To determine the efficacy of pegylated interferon alfa-2A in the treatment of refractory inflammatory cystoid macular edema (CME) Methods: Retrospective chart review Results: Treatment with pegylated interferon alfa-2A led to an improvement in ...
Hillary C. Stiefel +5 more
semanticscholar +1 more source
Purpose: To determine the efficacy of pegylated interferon alfa-2A in the treatment of refractory inflammatory cystoid macular edema (CME) Methods: Retrospective chart review Results: Treatment with pegylated interferon alfa-2A led to an improvement in ...
Hillary C. Stiefel +5 more
semanticscholar +1 more source
Ocular immunology and inflammation, 2019
Purpose: The aim of this study was to further explore the efficacy and safety of interferon-α in refractory non-infectious inflammatory macular edema and to compare interferon-α2a and pegylated interferon-α2b.
C. Couret +4 more
semanticscholar +1 more source
Purpose: The aim of this study was to further explore the efficacy and safety of interferon-α in refractory non-infectious inflammatory macular edema and to compare interferon-α2a and pegylated interferon-α2b.
C. Couret +4 more
semanticscholar +1 more source
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.
New England Journal of MedicineBACKGROUND In a phase 3 trial, bulevirtide monotherapy led to a virologic response in patients with chronic hepatitis D. Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as an off-label treatment for this disease.
T. Asselah +25 more
semanticscholar +1 more source
Pegylated interferons for chronic hepatitis B
Antiviral Research, 2003Conventional interferon therapy has been used for the treatment of chronic hepatitis B (CHB) for many decades. However, the use of interferon has been limited by its short half-life and high incidence of dose-related side effects. A meta-analysis investigating the short- and long-term consequences of interferon therapy showed that, whilst interferon ...
Craxi, A., Cooksley, W. G.
openaire +3 more sources
Journal of Neuroscience Nursing, 2014
Most multiple sclerosis (MS) therapies are injectable drugs, and the frequency of injections has been shown to be inversely proportional to overall compliance. One method of improving therapeutic compliance and thus clinical outcomes is to develop medications that require less frequent dosing. One of the most promising modification techniques to extend
Anne, Howley, Marcelo, Kremenchutzky
openaire +2 more sources
Most multiple sclerosis (MS) therapies are injectable drugs, and the frequency of injections has been shown to be inversely proportional to overall compliance. One method of improving therapeutic compliance and thus clinical outcomes is to develop medications that require less frequent dosing. One of the most promising modification techniques to extend
Anne, Howley, Marcelo, Kremenchutzky
openaire +2 more sources